STOCKWATCH
·
Medical Specialities
Quarterly ResultMay 13, 2026, 04:33 PM

Aclarion Q1 Revenue $21,140; Net Loss $(2.85M); Cash $19.0M

AI Summary

Aclarion reported a net loss of $(2.85) million for Q1 2026, an increase from $(2.04) million in Q1 2025, despite revenue growing to $21,140 from $18,991. The company's gross profit turned positive to $3,750 from a loss of $(4,488) in the prior year. Operating expenses significantly increased, but Aclarion bolstered its liquidity through a $10.4 million direct offering, ending the quarter with $19.0 million in cash and cash equivalents.

Key Highlights

  • Q1 2026 revenue increased to $21,140 from $18,991 in Q1 2025.
  • Gross profit turned positive to $3,750 in Q1 2026 from a loss of $(4,488) in Q1 2025.
  • Net loss for Q1 2026 was $(2.85) million, compared to $(2.04) million in Q1 2025.
  • Net loss per share improved to $(1.34) in Q1 2026 from $(9.32) in Q1 2025.
  • Cash and cash equivalents rose to $19.0 million as of March 31, 2026, from $12.0 million at Dec 31, 2025.
  • Total operating expenses increased to $2.99 million in Q1 2026 from $1.49 million in Q1 2025.
  • Completed a registered direct offering raising approximately $10.4 million in gross proceeds.
  • Company believes existing cash will fund operations for at least 12 months.
ACON
Medical Specialities
Aclarion, Inc.

Price Impact